Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Chief Scores With Congress On DME Bid Program, Telehealth Pay, But Says LDTs Complex

Executive Summary

At back-to-back congressional hearings on Feb. 14 and 15, US Health and Human Services Secretary Alex Azar seemed to satisfy lawmakers' questions on how he would use his budget to fix problems in the durable medical equipment bidding program and provide telehealth reimbursements under Medicare, but conceded that lab-developed test regulations are a complicated issue.

You may also be interested in...



Device Week, Feb. 9, 2018 – Last Night In Congress, And Digital-Health Discourse

On this week's podcast, we discuss US Congress' last-minute budget deal that included several Medicare provisions relevant to the medtech sector. And we talk about US FDA's recent two-day workshop on its Pre-Cert Pilot Program for digital health.

Medtech Provisions Approved In US Budget Agreement

Medtech and funding provisions in a two-year budget deal that the US Senate and House approved early Friday morning and which were signed by the President would extend Medicate telehealth programs, remove a rental cap for speech-generating devices and strengthen competitive bidding rules to assure access to diabetic test strips, among others. 

New HHS Chief Alex Azar Supports LDT Regulation, Cost-Saving Bundles

Alex Azar was confirmed as the next secretary of Health and Human Services with strong industry support. Azar comes to the role with some homework to do on key FDA medtech policies, but has expressed support for risk-based regulation of lab-developed tests and cost-saving bundled-payment models.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel